Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.67 |
| ▸ | GABRP | O00591 | 3/20 | 0.67 |
| ▸ | GABRD | O14764 | 3/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.67 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.67 |
| ▸ | GABRE | P78334 | 3/20 | 0.67 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.67 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8844868 | 1.00 | KMT2A (1.00) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9686097 | 0.86 | MEN1 (0.75) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL30297595 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9563515 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9563509 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL23424295 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9422490 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL15400204 | 0.84 | KMT2A (0.72) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9684191 | 0.83 | KMT2A (0.71) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| Ro-24-7429 SCHEMBL29736766 | 0.83 | MEN1 (0.70) | KMT2AMEN1PDE4DCNR1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | BARANOWITZ STEVEN (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025064458-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | BARANOWITZ STEVEN (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20230313325-A1 | METHODS FOR DETECTION OF PATHOGENIC INFECTIONS USING RED BLOOD CELL-CONTAINING PATIENT SAMPLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-10-05 | — | — | US | disclosed |
| EP-4146820-A1 | METHODS FOR DETECTION OF PATHOGENIC INFECTIONS USING RED BLOOD CELL-CONTAINING PATIENT SAMPLES | The Trustees of The University of Pennsylvania (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4138853-A1 | METHODS AND MATERIALS FOR TREATMENT OF FIBROSIS | The Schepens Eye Research Institute, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | EPX, CTSA, SERPINB1 | KMT2A 2561/4885MEN1 2783/4885PDE4D 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.